Efficacy and safety of neoadjuvant chemotherapy plus concurrent chemoradiotherapy in locally advanced nasopharyngeal cancer: A real-world study
Bulletin du Cancer · 2026-06 · 113 (6) · 719-728
DOI: 10.1016/j.bulcan.2026.02.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin du Cancer, 2026-06. Verfasst von Amine Lachgar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institut national d'oncologie, CHU Ibn Sina, Rabat, Morocco; Faculté de médecine et de pharmacie de Rabat, université Mohammed, Rabat, Morocco. Elect…. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms, Neoadjuvant Therapy, Chemoradiotherapy, Nasopharyngeal Carcinoma. Die Arbeit nennt 33 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION Treatment of locally advanced nasopharyngeal carcinoma with neoadjuvant chemotherapy followed by concomitant chemoradiotherapy has shown an overall survival advantage over concomitant chemoradiotherapy alone in several clinical trials. However, data on its efficacy in low- and intermediate incidence regions remains limited. The aim of this study is to assess the efficacy and toxicity of this approach in a Moroccan cohort. METHODS We conducted a retrospective analysis involving 95 patients with stage III-IVA nasopharyngeal carcinoma treated at the National Institute of Oncology in Rabat, Morocco, from January 2018 to December 2021. Eligible patients received at least one cycle of neoadjuvant chemotherapy prior to concomitant chemoradiotherapy. The collected data included patient characteristics, treatment regimens, and therapeutic outcomes, including overall survival, locoregional recurrence-free survival, distant metastasis-free survival, as well as acute toxicity. RESULTS Median follow-up was 41.5 months. The 5-year overall survival, locoregional recurrence-free survival, and distant metastasis-free survival rates were 67%, 81.3%, and 75.7%, respectively. Independent prognostic factors for overall survival included age (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institut national d'oncologie, CHU Ibn Sina, Rabat, Morocco; Faculté de médecine et de pharmacie de Rabat, université Mohammed, Rabat, Morocco. Electronic address: Lachgar.amine@gmail.com.
- Institut national d'oncologie, CHU Ibn Sina, Rabat, Morocco; Faculté de médecine et de pharmacie de Rabat, université Mohammed, Rabat, Morocco.
Zitieren
APA
Lachgar, A., Hassnaoui, I., Ngbwa, E. T., El Gueddari, R., Youssoufi, M. A., Adnane Tazi, M., Nouni, K., El Kacemi, H., Kebdani, T., & Hassouni, K. (2026). Efficacy and safety of neoadjuvant chemotherapy plus concurrent chemoradiotherapy in locally advanced nasopharyngeal cancer: A real-world study. Bulletin du Cancer, 113(6), 719-728. https://doi.org/10.1016/j.bulcan.2026.02.007
Vancouver
Lachgar A, Hassnaoui I, Ngbwa ET, El Gueddari R, Youssoufi MA, Adnane Tazi M, et al. Efficacy and safety of neoadjuvant chemotherapy plus concurrent chemoradiotherapy in locally advanced nasopharyngeal cancer: A real-world study. Bulletin du Cancer. 2026;113(6):719-728. doi:10.1016/j.bulcan.2026.02.007
BibTeX
@article{Lachgar2026,
author = {Lachgar, Amine and Hassnaoui, Imane and Ngbwa, Edith Tatiana and El Gueddari, Rania and Youssoufi, Moulay Ali and Adnane Tazi, Mohammed and Nouni, Karima and El Kacemi, Hanan and Kebdani, Tayeb and Hassouni, Khalid},
title = {Efficacy and safety of neoadjuvant chemotherapy plus concurrent chemoradiotherapy in locally advanced nasopharyngeal cancer: A real-world study},
journal = {Bulletin du Cancer},
year = {2026},
volume = {113},
number = {6},
pages = {719--728},
doi = {10.1016/j.bulcan.2026.02.007}
}
EUVIMED